Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
NCT04903327Phase 2Terminated
- Sponsor
- Sorrento Therapeutics
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of COVI-MSC in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Started Nov 2021; status: terminated.
02
Drugs
COVI-MSC
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04903327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903327.